Eczema–Psoriasis Overlap: An eDelphi Consensus on Clinical Presentation and Therapeutic Management Among Italian Experts

• by Eleonora De Luca, Anna Campanati, Marco Galluzzo, Niccolò Gori, Matteo Megna, Maddalena Napolitano, Giulia Rech, Giacomo Caldarola

• October 13, 2026

The Role of Inflammatory Biomarkers in Disease Severity and Treatment Response across Psoriasis, Atopic Dermatitis, and Hidradenitis Suppurativa—A Narrative Review

• by Julia Alicja Lewandowska, Agnieszka Owczarczyk–Saczonek

• May 19, 2026

Psoriasis–AD Switching May Mimic Treatment Failure

Recognizing sustained switches between the two diseases can prevent premature discontinuation of effective biologics and point toward Janus kinase inhibitors, a 148-patient cohort suggests.

• by Andrea Surnit

• June 15, 2026

• 4 min

Summary of Research: Apremilast Improves Skin Outcomes in Pediatric Plaque Psoriasis of Shorter Disease Duration: 52-Week Results from the SPROUT Phase 3 Trial

• by Richard G. Langley, Lisa Arkin, Loretta Fiorillo, Lawrence F. Eichenfield, Mark Lebwohl, Bruce Strober, Michael Sticherling, Lisa Swanson, Georgios Kokolakis, Siddharth Chaudhari, Cynthia Deignan, Zuoshun Zhang, Amy S. Paller

• May 14, 2026